Patents matching “anti-”

WO 2025090898

ANTICORPS ANTI-RÉCEPTEUR DE LA TRANSFERRINE ET LEURS UTILISATIONS - RÉFÉRENCES CROISÉES AUX DEMANDES CONNEXES

BIOGEN MA INC [US] · Granted May 1, 2025 · Expires Apr 26, 2045

US 12286479

Treatment with anti-α4β7 antibody

Takeda Pharmaceutical Company Limited · Granted Apr 29, 2025 · Expires Apr 24, 2045

US 12280063

Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12280029

Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

INSTITUT PASTEUR DE MONTEVIDEO · Granted Apr 22, 2025 · Expires Apr 17, 2045

TW 202515903

Anti-PD-1-based treatment before and after surgery

BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 16, 2025 · Expires Apr 11, 2045

US 12275786

Anti-thyroglobulin t cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 15, 2025 · Expires Apr 10, 2045

US 12269887

Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using

Regents of the University of Minnesota · Granted Apr 8, 2025 · Expires Apr 3, 2045

US 12269897

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2025 · Expires Apr 3, 2045

WO 2025070337

ANTICORPS AGONISTE ANTI-MERTK, ANTICORPS BISPÉCIFIQUE ANTI-MERTK ET LEUR UTILISATION

ASTELLAS PHARMA INC [JP] · Granted Apr 3, 2025 · Expires Mar 29, 2045

US 12263173

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

US 12263225

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

Dyne Therapeutics, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

US 12258412

Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12258401

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12252481

Anti-viral compounds

Aligos Therapeutics, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12251458

Anti-aging preparation for skin and application thereof

SOUTH CHINA NORMAL UNIVERSITY · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12251440

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12252544

Anti-CD63 antibodies, conjugates, and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12252746

Anti-CD46 antibodies and methods of use

The Regents of the University of California · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

US 12240917

Anti-complement C1s antibodies and uses thereof

Bioverativ USA Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

US 12240902

Anti-TREM2 antibodies and methods of use thereof

DENALI THERAPEUTICS INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

US 12239656

Nucleoporins as drug targets for anti-proliferative therapeutics

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Mar 4, 2025 · Expires Feb 27, 2045

WO 2025040080

TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE

BEIGENE SWITZERLAND GMBH [CH] · Granted Feb 27, 2025 · Expires Feb 22, 2045

US 12234294

Pharmaceutical composition of a humanized anti-CD40 antibody

Kiniksa Pharmaceuticals, GmbH · Granted Feb 25, 2025 · Expires Feb 20, 2045